Matthew Vincent Dolan net worth and biography

Matthew Dolan Biography and Net Worth

SVP of DexCom

Matt Dolan has served as Dexcom’s Executive Vice President of Strategy, Corporate Development & Dexcom Labs since September 2022.

Matt joined Dexcom in 2015 and has held various positions of increasing responsibility. In his current role, Matt is responsible for Dexcom’s corporate strategy and development functions, including long-range planning, strategic and competitive intelligence, partnerships, and M&A. Since its inception in 2019, he also oversees Dexcom’s New Markets incubator, which is focused on expanding the company’s value proposition across new areas of growth for both its Continuous Glucose Monitoring and other sensing capabilities. Before that, Matt’s responsibilities included support of Dexcom’s Investor Relations efforts.

With 20 years of experience in the medical technology space, Matt began his career as an equity analyst on Wall Street, a role he held for 10 years. After that, he held a leadership position in strategy and business development at Volcano Corporation through the company’s acquisition by Philips in 2015.

Matt earned a Bachelor’s degree in Economics/Pre-Medicine from Northwestern University.

What is Matthew Vincent Dolan's net worth?: The estimated net worth of Matthew Vincent Dolan is at least $3.16 million as of April 15th, 2024. Mr. Dolan owns 42,377 shares of DexCom stock worth more than $3,155,391 as of November 21st. This net worth estimate does not reflect any other assets that Mr. Dolan may own. Learn More about Matthew Vincent Dolan's net worth.
How old is Matthew Vincent Dolan?: Mr. Dolan is currently 43 years old. There are 6 older executives and no younger executives at DexCom. The oldest executive at DexCom is Mr. Kevin Ronald Sayer, Executive Chairman, CEO & President, who is 66 years old. Learn More on Matthew Vincent Dolan's age.
How do I contact Matthew Vincent Dolan?: The corporate mailing address for Mr. Dolan and other DexCom executives is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. DexCom can also be reached via phone at (858) 200-0200 and via email at [email protected]. Learn More on Matthew Vincent Dolan's contact information.
Has Matthew Vincent Dolan been buying or selling shares of DexCom?: Matthew Vincent Dolan has not been actively trading shares of DexCom during the past quarter. Most recently, Matthew Vincent Dolan sold 1,990 shares of the business's stock in a transaction on Monday, April 15th. The shares were sold at an average price of $137.81, for a transaction totalling $274,241.90. Following the completion of the sale, the executive vice president now directly owns 42,377 shares of the company's stock, valued at $5,839,974.37. Learn More on Matthew Vincent Dolan's trading history.
Who are DexCom's active insiders?: DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Michael Brown (EVP), Richard Collins (Director), Matthew Dolan (SVP), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (CEO), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.
Are insiders buying or selling shares of DexCom?: During the last twelve months, insiders at the medical device company sold shares 28 times. They sold a total of 252,409 shares worth more than $33,128,636.21. The most recent insider tranaction occured on September, 9th when EVP Sadie Stern sold 426 shares worth more than $29,457.90. Insiders at DexCom own 0.3% of the company. Learn More about insider trades at DexCom.
Information on this page was last updated on 9/9/2024.

Matthew Vincent Dolan Insider Trading History at DexCom

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/15/2024	Sell	1,990	$137.81	$274,241.90	42,377
9/1/2023	Sell	56	$102.32	$5,729.92	33,569
3/16/2023	Sell	2,303	$115.00	$264,845.00	33,569
3/13/2023	Sell	6,229	$106.27	$661,955.83	35,872
3/6/2023	Sell	226	$114.40	$25,854.40	26,536

Matthew Vincent Dolan Buying and Selling Activity at DexCom

DexCom Company Overview

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Today's Range

Now: $74.46

$74.14

$75.76

50 Day Range

MA: $70.43

$65.68

$76.27

2 Week Range

Now: $74.46

$62.34

$142.00

Volume

3,230,709 shs

Average Volume

3,924,849 shs

Market Capitalization

$29.08 billion

P/E Ratio

44.59

Dividend Yield

N/A

Beta

1.17

Blackrock’s Sending THIS Crypto Higher on Purpose

From Crypto 101 Media | Ad

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

YES, I WANT THE #1 CRYPTO NOW

Matthew Dolan Biography and Net Worth

What is Matthew Vincent Dolan's net worth?

How old is Matthew Vincent Dolan?

How do I contact Matthew Vincent Dolan?

Has Matthew Vincent Dolan been buying or selling shares of DexCom?

Who are DexCom's active insiders?

Are insiders buying or selling shares of DexCom?